Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study - Takeaways - MDSpire

Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study

  • By

  • Fredy Kahkedjian

  • Jaffer Shah

  • Firas Kreidieh

  • July 1, 2026

  • 0 min

Share

  • 1

    Tirzepatide is a dual agonist used in patients with type 2 diabetes and obesity, improving metabolic and cardiovascular risk factors.

  • 2

    A retrospective cohort study found that tirzepatide use significantly reduced the 12-month risk of pulmonary embolism compared to lifestyle intervention.

  • 3

    The study also reported a significant reduction in the risk of deep vein thrombosis associated with tirzepatide use.

  • 4

    No significant difference was observed for superficial vein thrombosis between tirzepatide and lifestyle intervention.

  • 5

    Tirzepatide's association with lower thromboembolic events was also noted in a comparator analysis with semaglutide.

Original Source(s)

Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study

  • by Fredy Kahkedjian, Jaffer Shah, Firas Kreidieh

  • July 1, 2026

Related Content

Nearly Four Million Medicare Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare GLP-1 Bridge

Preoperative Weight Loss: Helpful, Harmful or Irrelevant?

When one size doesn’t fit all: aciclovir dosing and the obesity challenge